GMAB News and Press, Genmab A/S From 01/30/24

2024-01-30 16:40:26 ET More on Johnson & Johnson Johnson & Johnson: Positioned To Receive Benefits Of Heavy R&D Investments Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy' Johnson & Johnson 2023 Q4 - Results -...

2024-01-23 16:29:32 ET Summary Genmab's appeal against Johnson & Johnson in an arbitration case has been denied, eliminating the potential upside for the company. Despite this setback, Genmab remains well positioned to create shareholder value through continued revenue growth ...

2024-01-23 07:56:29 ET More on Genmab, J&J, etc. Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off? Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition Genmab: 3 Trends To Track For A Strong 2024 And Beyo...

2024-01-23 07:08:06 ET More on Genmab, Johnson & Johnson, etc. Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off? Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition Genmab: 3 Trends To Track For A Strong...

2024-01-19 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-16 08:22:47 ET Losers: Allakos ALLK -54% announces on restructuring plans . Applied UV ( AUVI ) -18% announces receipt of significant orders in smart building technologies division . Applied Digital Corporation APLD -12% after Q2 earnings rele...

2024-01-11 23:20:33 ET Summary Genmab is a leading contender in the biotech industry with innovative technology, a robust pipeline, and strategic collaborations. Epcoritamab's growth is a positive trend to monitor, as it has shown impressive financial performance and secured regul...

2024-01-09 07:13:52 ET More on Genmab, Pfizer, etc. Pfizer Inc. (PFE) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Pfizer: 50% Down From The Highs, Generous Dividend, And Robust Balance Sheet Pfizer: Paying Too Much To Boost Revenues Pfizer wins...

– Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy – Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has accepted...

TIVDAK sBLA accepted for priority review, FDA action date is May 9, 2024 Submission based on positive results from global phase 3 innovaTV 301 trial demonstrating overall survival benefit of tisotumab vedotin-tftv over chemotherapy Genmab A/S (Nasdaq: GMAB) and Pfizer, I...